Table 1.
Clinical characteristics and outcomes of patients treated with meropenem/vaborbactam (MVB) for infections caused by carbapenem-resistant Enterobacterales (CRE)
| Age (years) | Sex | CRE species (source) | Other susceptibilities | Primary infection | Major comorbidities | ICU | Source control | MVB dosing regimen (CrCl)a | Duration of therapy (days) | Clinical response | Microbiological response at Day 3/7 | Recurrence free at Day 30/90 | Survival at Day 30/90 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 83 | F | K. pneumo (tissue) | AMK, GEN, MIN | PJI | CKD, DM | N | Partial | 2 g q12h (31 mL/m in) | 45 | Neg. | ND/ND | −/− | Y/Y |
| 62 | M | K. pneumo (urine) | CZA | UTI | DLBCL, IBD | Y | N/A | 2 g q12h (22 mL/m in) | 4 | Neg. | Pos./Pos. | −/− | N/− (unrelated) |
| 38 | F | C. Koseri (tissue) | AMK, CZA, SXT | Osteomyelitis | DM | N | Yes | Full doseb | 41 | Pos. | ND/ND | UC/− | Y/Y |
| 53 | M | K. pneumo (blood) | AMK, CZA, GEN, TET, SXT, TOB | Soft tissue abscess with secondary bacteraemia | CLD | N | Yes | Full doseb | 14 | Pos. | Pos./Pos. | N/− | Y/Y |
| 63 | M | E. coli (tissue) | CZA, GEN, LVX | Osteomyelitis | PVD | N | Yes | Full doseb | 39 | Pos. | ND/ND | Y/Y | Y/Y |
| 46 | M | E. coli (abscess) | AMK, CZA, SXT | Intra-abdominal abscess | CKD, DM, SOT | N | Yes | Full doseb | 27 | Pos. | ND/ND | Y/Y | Y/Y |
| 52 | F | K. pneumo (sputum) | AMK, CZA, GEN | VAP | CAD, CHF, CKD, DM | Y | N/A | Full doseb | 7 | Neg. | Neg./− | −/− | N/− (unrelated) |
| 79 | F | K. pneumo (blood) | CZA | CLABSI | CHF, CLD, DM | Y | Yes | 2 g q8h (33 mL/m in) | 17 | Pos. | Neg./Pos. | Y/Y | Y/Y |
| 53 | M | E. coli (tissue) | AMK, CZA, GEN, SXT, TOB | Osteomyelitis/SS TI | CHF, CLD, CVA, DM, ESRD, PVD | N | Yes | 1 g q12h (<15 mL/m in) | 50 | UC | ND/ND | UC/− | Y/Y |
| 62 | M | K. pneumo (sputum) | CZA, SXT | PNA | mSCC | Y | N/A | Full doseb | 8 | Pos. | ND/Pos. | Y/Y | Y/Y |
| 36 | M | K. aerogenes (abscess) | AMK, GEN, SXT, TOB | Intra-abdominal abscess | None | Y | Partial | Full doseb | 7 | Neg. | ND/ND | −/− | Y/Y |
| 82 | F | K. pneumo (tissue) | CZA | Osteomyelitis | CKD, COPD, DM | N | Yes | Full doseb | 34 | Pos. | ND/ND | Y/Y | Y/Y |
| 70 | M | K. pneumo (blood) | None | Primary bacteraemia | ALL, CAD, CHF | Y | N/A | Full doseb | 14 | Pos. | Pos./Pos. | Y/Y | Y/Y |
| 90+ | F | K. pneumo (urine) | AMK, CZA, GEN, TET, SXT, TOB | UTI | CAD | Y | N/A | 2 g q8h (60 mL/m in) | 5 | Neg. | ND/ND | −/− | N/− (related) |
| 68 | M | K. pneumo (blood) | AMK, CZA, FDC | Primary bacteraemia | CAD, COPD, PVD | N | N/A | Full doseb | 27 | Pos. | Pos./Pos. | Y/Y | Y/Y |
ALL, acute lymphoblastic leukaemia; AMK, amikacin; CAD, coronary artery disease; CHF, congestive heart failure; CKD, chronic kidney disease; C. koseri, Citrobacter koseri; CLABSI, central line-associated bloodstream infection; CLD, chronic liver disease; COPD, chronic obstructive pulmonary disease; CrCl, creatinine clearance; CVA, cerebrovascular accident; CZA, ceftazidime/avibactam; DLBCL, diffuse large B-cell lymphoma; DM, diabetes mellitus; E. coli, Escherichia coli; ESRD, end-stage renal disease; FDC, cefiderocol; GEN, gentamicin; IBD, inflammatory bowel disease; ICU, intensive care unit; K. aerogenes, Klebsiella aerogenes; K. pneumo, Klebsiella pneumoniae; LVX, levofloxacin; MIN, minocycline; mSCC, metastatic squamous cell carcinoma; N, no; N/A, not applicable; ND, not determined; Neg., negative response; PJI, prosthetic joint infection; PNA, pneumonia; Pos., positive response; PVD, peripheral vascular disease; q12h, every 12 h; q8h, every 8 h; SOT, solid organ transplant; SSTI, skin and soft-tissue infection; SXT, trimethoprim/sulfamethoxazole; TET, tetracycline; TOB, tobramycin; UC, uncertain; UTI, urinary tract infection; VAP, ventilator-associated pneumonia; Y, yes; –, not applicable.
CrCl calculated using the Cockcroft–Gault equation.
MVB full dose = 4 g q8h.